Results 101 to 110 of about 14,237 (205)
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
eLife, 2015 The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between ...
Irawati Kandela +3 more
doaj +1 more source
, 2016 The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models.
Council, L. N. +4 more
core +1 more source
, 2022 Die niedermolekulare Verbindung (engl. small molecule) JQ1 hemmt kompetitiv die Bromodomänen der zur bromodomain and extra-terminal domain (BET) Familie gehörenden Proteine BRD2, BRD3 und BRD4, welche als epigenetische Lesedomänen auf die Transkription ...
Schlichting, Jara Pascale
core
, 2020 JQ1 is a small-molecule inhibitor of the bromodomain and extra terminal (BET) protein family that potently inhibits the bromodomain testis-specific protein (BRDT), which is essential for spermatogenesis.
Santini, Conrad +5 more
core +1 more source
BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells
, 2017 Anaplastic thyroid carcinoma (ATC) represents the most lethal thyroid cancer sub-type, currently unresponsive to standard treatments. Recently, bromodomain and extra-terminal (BET) proteins have emerged as attractive therapeutic targets in several ...
Catia Mio +17 more
core +1 more source
EBioMedicine, 2019 Background: DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1 increases levels of DNA damage, we evaluated the efficacy of JQ1 + the PARPi olaparib in ...
Aubrey L. Miller +8 more
doaj +1 more source
Bromodomain Inhibitor JQ1 as a Candidate Therapeutic Agent in Malignant Pleural Mesothelioma
, 2020 Malignant pleural mesothelioma (MPM) is a rare tumor that develops from the mesothelial linings of the pleural, pericardial, and peritoneal cavities. The actual risk factor for developing the disease is exposure to asbestos in workplace.
Albadri, Cinaria T.
core +1 more source
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Journal for ImmunoTherapy of Cancer, 2019 Background Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus susceptible to immune targeting ...
Wendy Mao +8 more
doaj +1 more source
Polydopamine-Based Nanoparticles for Synergistic Chemotherapy of Prostate Cancer
International Journal of NanomedicineKebang Hu,1 Dongqi Zhang,1 Weiran Ma,2 Yanzhi Gu,2 Jiang Zhao,3 Xupeng Mu4 1Department of Urology, Lequn Branch, The First Hospital of Jilin University, Changchun, 130031, People’s Republic of China; 2College of Pharmacy, Jilin University, Changchun ...
Hu K, Zhang D, Ma W, Gu Y, Zhao J, Mu X
doaj
The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.
PLoS ONE, 2017 BackgroundSome latency-reversing agents (LRAs) inhibit HIV-specific CD8+ T cell responses. In a prior study of protein kinase C (PKC) agonists, we found that bryostatin-1 inhibited elite controller/suppressor (ES) CD8+ T cell suppressive activity whereas
Abena K Kwaa +5 more
doaj +1 more source